Reduced serum levels of a soluble form of the human adhesion receptor CD58 (LFA-3) in patients with inflammatory bowel disease.

The activation of monocytes, neutrophils, and B cells by T-lymphocytes appears to play a pivotal role in the pathophysiology of inflammatory bowel disease. The pan T cell marker CD2 and its ligand CD58 mediate these immune function. We asked whether serum levels of a soluble form of CD58 is altered in patients with inflammatory bowel disease. Soluble CD58 was measured in sera from 41 patients with Crohn's disease, 19 patients with ulcerative colitis, and 24 normal controls. Soluble CD58 levels were significantly decreased in sera from patients with ulcerative colitis and even more with Crohn's disease when compared to controls (p = 0.025 and p < 0.0001, respectively). Reduction of soluble CD58 serum levels correlated significantly with various humoral (e.g. erythrocyte sedimentation rate: r = -0.48, p = 0.0002) and clinical parameters of disease activity (e.g. CDAI: r = -0.44, p = 0.005). In conclusion, serum levels of soluble CD58 are reduced in patients with inflammatory bowel disease. Since soluble CD58 can block the CD2/CD58 interaction further studies have to show whether the reduction of soluble CD58 in patients with inflammatory bowel disease contributes to T cell adhesiveness in the mucosa.